Madrigal Pharmaceuticals (MDGL) Exchange Rate Effect (2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Exchange Rate Effect of $57000.0 for Q2 2026, down 95.68% quarter-over-quarter from $1.3 million in Q1 2026.
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Exchange Rate Effect (2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Exchange Rate Effect for 1 consecutive years, with $57000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Exchange Rate Effect changed N/A year-over-year to $57000.0; the TTM figure through Jun 2026 stood at $1.4 million (changed N/A YoY), while the FY2025 annual figure was $13000.0, changed N/A from the prior year.
- Exchange Rate Effect declined to $57000.0 in Q2 2026 per MDGL's latest filing, from $1.3 million in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $1.3 million in Q1 2026 and bottomed at $57000.0 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -287,000.00 |
| 10 | Madrigal Pharmaceuticals | 15.76 Bn | 14.93 Bn | - | 57,000.00 |